Kiniksa Pharmaceuticals International, plc(KNSA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #138 of 2,961 stocksTOP 5%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
KNSA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Kiniksa Pharmaceuticals International, plc (KNSA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KNSA at 73.2/100 on a 32-signal composite quality model, placing it at rank #138 of 2,961 stocks — the top 5% of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2026), Kiniksa Pharmaceuticals International, plc reports quarterly revenue of $214.3M, net income of $22.6M, an operating margin of 13.7%. Top institutional holders of KNSA by reported 13-F value include FMR, Rubric Capital Management, BAKER BROS. ADVISORS, based on the most recent SEC filings. KNSA trades on the Nasdaq exchange and files with the SEC under CIK 1730430. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KNSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kiniksa Pharmaceuticals International, plc directly from SEC EDGAR.
Revenue
Q1 2026
$214.3M
Net Income
Q1 2026
$22.6M
Free Cash Flow
Q1 2026
$50.0M
Operating Margin
Q1 2026
13.7%
ROIC
Q1 2026
19.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+60.1% YoYNet Income
+236.6% YoYOperating Income
+269.3% YoYEPS (Diluted)
+225.0% YoYTotal Assets
+31.5% YoYOp. Cash Flow
+437.1% YoYFree Cash Flow
+436.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $677.6M +60.1% | $423.2M +56.6% | $270.3M +22.7% | $220.2M +471.2% | $38.5M | — |
| Net Income | $59.0M +236.6% | $-43.2M -406.7% | $14.1M -92.3% | $183.4M +216.1% | $-157.9M +2.1% | $-161.4M |
| Operating Income | $77.2M +269.3% | $-45.6M -81.0% | $-25.2M -357.8% | $9.8M +106.2% | $-156.6M +0.5% | $-157.4M |
| EPS (Diluted) | $0.75 +225.0% | $-0.60 -400.0% | $0.20 -92.3% | $2.60 +213.0% | $-2.30 +11.9% | $-2.61 |
| Total Assets | $763.6M +31.5% | $580.6M +10.3% | $526.3M +14.5% | $459.7M +97.5% | $232.8M -33.4% | $349.5M |
| Operating Cash Flow | $138.0M +437.1% | $25.7M +93.1% | $13.3M +129.1% | $5.8M +104.6% | $-126.3M +7.5% | $-136.5M |
| Free Cash Flow | $136.4M +436.8% | $25.4M +92.9% | $13.2M +131.0% | $5.7M +104.5% | $-126.7M +7.4% | $-136.8M |
Get alerted when KNSA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kiniksa Pharmaceuticals International, plc including:
Top Institutional Holders of KNSA
FMR LLC
$445.8M6,971,361 shRubric Capital Management LP
$255.8M3,999,800 shBAKER BROS. ADVISORS LP
$181.3M2,834,643 shBlackRock, Inc.
$175.2M2,739,615 shTANG CAPITAL MANAGEMENT LLC
$144.5M2,259,889 shVANGUARD PORTFOLIO MANAGEMENT LLC
$122.2M1,911,335 shVANGUARD CAPITAL MANAGEMENT LLC
$87.0M1,360,840 shMORGAN STANLEY
$64.7M1,011,143 shARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$61.2M957,514 shSpruce Street Capital LP
$58.7M918,070 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $445.8M | 6,971,361 |
| Rubric Capital Management LP | $255.8M | 3,999,800 |
| BAKER BROS. ADVISORS LP | $181.3M | 2,834,643 |
| BlackRock, Inc. | $175.2M | 2,739,615 |
| TANG CAPITAL MANAGEMENT LLC | $144.5M | 2,259,889 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $122.2M | 1,911,335 |
| VANGUARD CAPITAL MANAGEMENT LLC | $87.0M | 1,360,840 |
| MORGAN STANLEY | $64.7M | 1,011,143 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $61.2M | 957,514 |
| Spruce Street Capital LP | $58.7M | 918,070 |
Companies Similar to KNSA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Krystal Biotech, Inc.
ACADIA PHARMACEUTICALS INC
LIGAND PHARMACEUTICALS INC
VERACYTE, INC.
RIGEL PHARMACEUTICALS INC
NEUROCRINE BIOSCIENCES INC
Arcutis Biotherapeutics, Inc.
Vericel Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KNSA on your watchlist
Track score changes the day Kiniksa Pharmaceuticals International, plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KNSA a good stock to buy?
13F Pro's AI-powered analysis of Kiniksa Pharmaceuticals International, plc (KNSA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KNSA are available on the KNSA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KNSA is classified as a mid company.
Which hedge funds own KNSA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KNSA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kiniksa Pharmaceuticals International, plc's investment landscape.